Vericel Corp (VCEL) – Company Profile and SWOT Analysis

Vericel Corp (VCEL) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Vericel Corp (Vericel) is a biopharmaceutical company that develops, markets, and commercializes advanced cell therapy products for sports medicine and severe burn care. Vericel's major products are MACI, an autologous cultured chondrocyte implant for treating knee cartilage defects, and Epicel, a cultured epidermal autograft used in the treatment of severe burns. The company holds an exclusive license for NexoBrid, a biological product for eschar removal in burn care. Vericel's products are sold through sports medicine, orthopedic surgeons, and specialized burn centers through cell therapy specialists in the US. The company collaborates with partners for the commercialization of its products outside the US. Vericel operates manufacturing facilities in the US. Vericel is headquartered in Cambridge, Massachusetts, the US

Scope

• Detailed information on Vericel Corp required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Vericel Corp in the form of a SWOT analysis

• An in-depth view of the business model of Vericel Corp including a breakdown and examination of key business segments

• News about Vericel Corp, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Vericel Corp and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Vericel Corp as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Vericel Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Stryker Corp

Arthrex Inc

CONMED Corp

Zimmer Biomet Holdings Inc

Aesculap Biologics LLC

AlloSource

Avita Medical Americas LLC

Anika Therapeutics Inc

Smith & Nephew Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Vericel Corp - Key Facts

Vericel Corp - Key Employees

Vericel Corp - Key Employee Biographies

Vericel Corp - Major Products and Services

Vericel Corp - History

Vericel Corp - Company Statement

Vericel Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Vericel Corp - Business Description

Product Category: Epicel

Overview

Performance

Product Category: MACI

Overview

Performance

Product Category: NexoBrid

Overview

Performance

R&D Overview

Vericel Corp - Corporate Strategy

Vericel Corp - SWOT Analysis

SWOT Analysis - Overview

Vericel Corp - Strengths

Vericel Corp - Weaknesses

Vericel Corp - Opportunities

Vericel Corp - Threats

Vericel Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Recent Developments

Mar 04, 2026: Vericel Receives FDA Approval for New Advanced Therapy Manufacturing Facility

Mar 04, 2026: Vericel Announces FDA Approval of New State-Of-The-Art Advanced Therapy Manufacturing Facility

Mar 03, 2026: Vericel to Present at Multiple Upcoming Investor Conferences

Jan 13, 2026: Vericel Announces Preliminary 2025 Financial Results and Business Updates

Jan 06, 2026: Vericel To Present At 44th Annual J.P. Morgan Healthcare Conference

Nov 06, 2025: Vericel Reports Third Quarter 2025 Financial Results

Jul 31, 2025: Vericel Reports Second Quarter 2025 Financial Results

May 08, 2025: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

Feb 27, 2025: Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 14, 2025: Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

Section 5 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Vericel Corp, Key Facts

Vericel Corp, Key Employees

Vericel Corp, Key Employee Biographies

Vericel Corp, Major Products and Services

Vericel Corp, History

Vericel Corp, Other Locations

Vericel Corp, Subsidiaries

Vericel Corp, Key Competitors

Vericel Corp, Ratios based on current share price

Vericel Corp, Annual Ratios

Vericel Corp, Annual Ratios (Cont…1)

Vericel Corp, Annual Ratios (Cont…2)

Vericel Corp, Interim Ratios

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Vericel Corp, Performance Chart (2021 – 2025)

Vericel Corp, Ratio Charts

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports